Community Oncology Reacts to Trump’s Drug Pricing Executive Order
Source: AJMC, May 2025
An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
The original plan for the session, “The Impact of Politics and Policy on Community Oncology,” a panel discussion at the 2025 Community Oncology Conference from the Community Oncology Alliance (COA), was for the assembled experts, moderated by Ted Okon, MBA, executive director of COA, to discuss the recent upheaval in Washington, DC—in particular, the personnel changes and legislative issues. However, an executive order signed on Tuesday, March 15, necessitated a change in plans.
This executive order from President Donald J. Trump is meant to target anticompetitive behavior in the drug market through increased transparency of pharmacy benefit manager (PBM) fees, lowering of drug prices, reforms to the Medicare Drug Price Negotiation Program, and promoting competition for high-cost prescription drugs.